DRUG · Unmapped registry intervention
BG00012
Find medicine records ·
Find other trials using this name
Clinical trial
Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
NCT00420212
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Placebo
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedEfficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
Sponsors & collaborators
Biogenlead sponsor
Mapped research locations
St LouisMissouri, United States1AtlantaGeorgia, United States1San AntonioTexas, United States1San FranciscoCalifornia, United States1LondonUnited Kingdom1SeattleWashington, United States1ParisFrance1PittsburghPennsylvania, United States1BerlinGermany1Washington D.C.District of Columbia, United States1IndianapolisIndiana, United States1PhoenixArizona, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00420212 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.